Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Preventive treatment in migraine and the new US guidelines
Authors Estemalik E, Tepper S
Received 11 December 2012
Accepted for publication 18 March 2013
Published 17 May 2013 Volume 2013:9 Pages 709—720
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
E Estemalik, S Tepper
Cleveland Clinic, Neurological Center for Pain, Cleveland, Ohio, USA
Abstract: Migraine headaches are among the most common headache disorders seen in various practices. The prevalence of migraine headaches is 18% in women and 6% in men. While millions of Americans suffer from migraine headaches, roughly 3%–13% of identified migraine patients are on preventive therapy, while an estimated 38% actually need a preventive agent. The challenge among physicians is not only when to start a daily preventive agent but which preventive agent to choose. Circumstances warranting prevention have been described in the past, and in 2012, a new set of guidelines with an evidence review on preventive medications was published. A second set of guidelines provided evidence on nonsteroidal anti-inflammatory drugs, herbs, minerals, and vitamins for prevention of episodic migraine. This article describes the updated US guidelines for the prevention of migraines and also outlines the major studies from which these guidelines were derived.
Keywords: US guidelines, Canadian guidelines, classification, preventive medication
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.